Recent advances in Staphylococcus aureus infection: focus on vaccine development

References

• Mermel LA, Cartony JM, Covington P, Maxey G, Morse D. Methicillin-resistant Staphylococcus aureus colonization at different body sites: a prospective, quantitative analysis. J Clin Microbiol. 2011;49(3):1119–1121. doi:10.1128/JCM.02601-1021209169
   PubMed Web of Science ®Google Scholar
• Kaspar U, Kriegeskorte A, Schubert T, et al. The culturome of the human nose habitats reveals individual bacterial fingerprint patterns. Environ Microbiol. 2016;18(7):2130–2142. doi:10.1111/1462-2920.1289125923378
   PubMed Web of Science ®Google Scholar
• Thammavongsa V, Kern JW, Missiakas DM, Schneewind O. Staphylococcus aureus synthesizes adenosine to escape host immune responses. J Exp Med. 2009;206:2417–2427. doi:10.1084/jem.2009009719808256
   PubMed Web of Science ®Google Scholar
• Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Investig. 2003;111:1265–1273. doi:10.1172/JCI1853512727914
   PubMed Web of Science ®Google Scholar
• Antri K, Akkou M, Bouchiat C, et al. High levels of Staphylococcus aureus and MRSA carriage in healthy population of algiers revealed by additional enrichment and multisite screening. Eur J Clin Microbiol Infect Dis. 2018;37(8):1521–1529. doi:10.1007/s10096-018-3279-629948361
   PubMed Web of Science ®Google Scholar
• Kazimoto T, Abdulla S, Bategereza L, et al. Causative agents and antimicrobial resistance patterns of human skin and soft tissue infections in Bagamoyo, Tanzania. Acta Trop. 2018;186:102–106. doi:10.1016/j.actatropica.2018.07.00730006029
   PubMed Web of Science ®Google Scholar
• Deguchi H, Kitazawa K, Kayukawa K, et al. The trend of resistance to antibiotics for ocular infection of Staphylococcus aureus, coagulase-negative staphylococci, and corynebacterium compared with 10-years previous: a retrospective observational study. PLoS One. 2018;13(9):e0203705. doi:10.1371/journal.pone.020370530192856
   PubMed Web of Science ®Google Scholar
• Belyhun Y, Moges F, Endris M, et al. Ocular bacterial infections and antibiotic resistance patterns in patients attending Gondar teaching hospital, Northwest Ethiopia. BMC Res Notes. 2018;11:597. doi:10.1186/s13104-018-3705-y30119696
   PubMedGoogle Scholar
• Keihanian F, Saeidinia A, Abbasi K, Keihanian F. Epidemiology of antibiotic resistance of blood culture in educational hospitals in Rasht, North of Iran. Infect Drug Resist. 2018;11:1723–1728. doi:10.2147/IDR.S16917630349329
   PubMed Web of Science ®Google Scholar
• Yadav NS, Sharma S, Chaudhary DK, et al. Bacteriological profile of neonatal sepsis and antibiotic susceptibility pattern of isolates admitted at Kanti children’s hospital, Kathmandu, Nepal. BMC Res Notes. 2018;11:301. doi:10.1186/s13104-018-3394-629764503
   PubMedGoogle Scholar
• Dat VQ, Vu HN, Nguyen The H, et al. Bacterial bloodstream infections in a tertiary infectious diseases hospital in Northern Vietnam: aetiology, drug resistance, and treatment outcome. BMC Infect Dis. 2017;17(1):493. doi:10.1186/s12879-017-2757-228701159
   PubMed Web of Science ®Google Scholar
• Huttunen R, Attman E, Aittoniemi J, et al. Nosocomial bloodstream infections in a finnish tertiary care hospital: a retrospective cohort study of 2175 episodes during the years 1999–2001 and 2005–2010. Infect Dis. 2015;47(1):20–26. doi:10.3109/00365548.2014.956791
   PubMed Web of Science ®Google Scholar
• Buetti N, Lo Priore E, Atkinson A, et al. Low incidence of subsequent bacteraemia or fungaemia after removal of a colonized intravascular catheter tip. Clin Microbiol Infect. 2018;24:548e1–548e3. doi:10.1016/j.cmi.2017.09.009
   Web of Science ®Google Scholar
• Pant S, Patel NJ, Deshmukh A, et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. J Am Coll Cardiol. 2015;65(19):2070–2076. doi:10.1016/j.jacc.2015.03.51825975469
   PubMed Web of Science ®Google Scholar
• Walaszek M, Różańska A, Walaszek MZ, Wójkowska-Mach J. The Polish society of hospital infections team. Epidemiology of ventilator-associated pneumonia, microbiological diagnostics and the length of antimicrobial treatment in the polish intensive care units in the years 2013–2015. BMC Infect Dis. 2018;18:308. doi:10.1186/s12879-018-3109-629976151
   PubMed Web of Science ®Google Scholar
• Huang Y, Jiao Y, Zhang J, et al. Microbial etiology and prognostic factors of ventilator-associated pneumonia: a multicenter retrospective study in Shanghai. Clin Infect Dis. 2018;67(S2):S146–S152. doi:10.1093/cid/ciy68630423049
   PubMed Web of Science ®Google Scholar
• Bonell A, Azarrafiy R, Huong VTL, et al. A systematic review and meta-analysis of ventilator-associated pneumonia in adults in Asia: an analysis of national income level on incidence and etiology. Clin Infect Dis. 2018;68(3):511–518. doi:10.1093/cid/ciy543
   Web of Science ®Google Scholar
• Rosenthal VD, Maki DG, Mehta A, et al. International nosocomial infection control consortium members. International report, data summary for 2002–2007. Am J Infect Control. 2008;36:627–637. doi:10.1016/j.ajic.2008.03.00318834725
   PubMed Web of Science ®Google Scholar
• Rosenthal VD, Al-Abdely HM, El-Kholy AA, et al. International nosocomial infection control consortium report, data summary of 50 countries for 2010–2015: device-associated module. Am J Infect Control. 2016;44:1495–1504. doi:10.1016/j.ajic.2016.08.00727742143
   PubMed Web of Science ®Google Scholar
• Jan W, Sebastian H, Chantal Q, et al. Healthcare-associated pneumonia in acute care hospitals in European Union/European Economic area countries: an analysis of data from a point prevalence survey, 2011 to 2012. Euro Surveill. 2018;23(32):1700843.
   Google Scholar
• El-Sokkary RH, Ramadan RA, El-Shabrawy M, et al. Community acquired pneumonia among adult patients at an Egyptian university hospital: bacterial etiology, susceptibility profile and evaluation of the response to initial empiric antibiotic therapy. Infect Drug Resist. 2018;11:2141–2150. doi:10.2147/IDR.S18277730464557
   PubMed Web of Science ®Google Scholar
• Akil N, Muhlebach MS. Biology and management of methicillin resistant Staphylococcus aureus in cystic fibrosis. Pediat Pulmonol. 2018;53:S64–S74. doi:10.1002/ppul.24139
   PubMed Web of Science ®Google Scholar
• Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109:309–318. doi:10.1179/2047773215Y.000000003026343252
   PubMed Web of Science ®Google Scholar
• Mannaa D, Mandal AK, Sen IK, et al. Antibacterial and DNA degradation potential of silver nanoparticles synthesized via green route. Int J Biol Macromol. 2015;80:455–459. doi:10.1016/j.ijbiomac.2015.07.02826188293
   PubMed Web of Science ®Google Scholar
• Alabi AS, Frielinghaus L, Kaba H, et al. Retrospective analysis of antimicrobial resistance and bacterial spectrum of infection in Gabon, central Africa. BMC Infect Dis. 2013;13:455. doi:10.1186/1471-2334-13-45524083375
   PubMed Web of Science ®Google Scholar
• Nurjadi D, Friedrich-Jänicke B, Schäfer J, et al. Skin and soft tissue infections in intercontinental travellers and the import of multi-resistant Staphylococcus aureus to Europe. Clin Microbiol Infect. 2015;21:567e1–10. doi:10.1016/j.cmi.2015.01.01625753191
   PubMed Web of Science ®Google Scholar
• Klein EY, Sun L, Smith DL, Laxminarayan R. The changing epidemiology of methicillin-resistant Staphylococcus aureus in the United States: a national observational study. Am J Epidemiol. 2013;177:666–674. doi:10.1093/aje/kws27323449778
   PubMed Web of Science ®Google Scholar
• Santajit S, Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. Biomed Res Int. 2016;2016:2475067. doi:10.1155/2016/247506727274985
   PubMed Web of Science ®Google Scholar
• Ansari S, Nepal HP, Gautam R, et al. Threat of drug resistant Staphylococcus aureus to health in Nepal. BMC Infect Dis. 2014;14:157. doi:10.1186/1471-2334-14-15724655316
   PubMed Web of Science ®Google Scholar
• Ansari S, Nepal HP, Gautam R, et al. Staphylococcus aureus: methicillin resistance and small colony variants from pyogenic infections of skin, soft tissue and bone. J Nepal Health Res Counc. 2015;13(30):126–132.26744197
   PubMedGoogle Scholar
• ECDC. European Centre for Disease Prevention and Control. 2011 Annual epidemiological report 2011. Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Available from: https://ecdc.europa.eu/en/publications-data/annual-epidemiological-report-2011-2009-data. Accessed November 10, 2011.
   Google Scholar
• Najafi A. There is no escape from the ESKAPE pathogens; 2016 Available from: https://emerypharma.com/blog/eskapepathogens-explained/. Accessed November 29, 2016.
   Google Scholar
• Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States; 2013 Available from: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed April, 2013.
   Google Scholar
• Jean -S-S, Hsueh P-R. High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents. 2011;37(4):291–295. doi:10.1016/j.ijantimicag.2011.01.00921382699
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Active bacterial core surveillance report, methicillin-resistant Staphylococcus aureus; 2012 Available from: https://www.cdc.gov/abcs/reports-findings/survreports/mrsa12.html. Accessed March 7, 2014.
   Google Scholar
• Wojtyczka RD, Dziedzic A, Kepa M, et al. Berberine enhances the antibacterial activity of selected antibiotics against coagulase-negative staphylococcus strains in vitro. Molecules. 2014;19:6583–6596. doi:10.3390/molecules1905658324858093
   PubMed Web of Science ®Google Scholar
• Tian L, Sun Z, Zhang Z. Antimicrobial resistance of pathogens causing nosocomial bloodstream infection in Hubei Province, China, from 2014 to 2016: a multicenter retrospective study. BMC Public Health. 2018;18:1121. doi:10.1186/s12889-018-6013-530219056
   PubMed Web of Science ®Google Scholar
• You JHS, Choi KW, Wong TY, et al. Disease burden, characteristics, and outcomes of methicillin-resistant Staphylococcus aureus bloodstream infection in Hong Kong. Asia Pac J Public Health. 2017;29(5):451–461. doi:10.1177/101053951771736528719790
   PubMed Web of Science ®Google Scholar
• Lim WW, Wu P, Bond HS, et al. Determinants of MRSA prevalence in the Asia Pacific Region: a systematic review and meta-analysis. J Global Antimicrobial Resist. 2018;16:17–27. doi:10.1016/j.jgar.2018.08.014
   Web of Science ®Google Scholar
• Gurunathan S, Han JW, Kwon DN, Kim JH. Enhanced antibacterial and antibiofilm activities of silver nanoparticles against gram-negative and gram-positive bacteria. Nanoscale Res Lett. 2014;9:373. doi:10.1186/1556-276X-9-37325136281
   PubMed Web of Science ®Google Scholar
• DeLeo FR, Chambers HF. Re-emergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest. 2009;119:2464–2474. doi:10.1172/JCI3822619729844
   PubMed Web of Science ®Google Scholar
• Herigon JC, Hersh AL, Gerber JS, Zaoutis TE, Newland JG. Antibiotic management of Staphylococcus aureus infections in US children’s hospitals, 1999–2008. Pediatrics. 2010;125(6):e1294–e300. doi:10.1542/peds.2009-286720478934
   PubMed Web of Science ®Google Scholar
• Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666–674. doi:10.1056/NEJMoa05535616914702
   PubMed Web of Science ®Google Scholar
• Mandal SM, Ghosh AK, Pati BR. Dissemination of antibiotic resistance in methicillin-resistant Staphylococcus aureus and vancomycin-resistant S. aureus strains isolated from hospital effluents. Am J Infect Control. 2015;43:e87–e8. doi:10.1016/j.ajic.2015.08.01526422180
   PubMed Web of Science ®Google Scholar
• Khamash DF, Voskertchian A, Tamma PD, et al. Increasing clindamycin and trimethoprim-sulfamethoxazole resistance in pediatric Staphylococcus aureus infections. J Pediatric Infect Dis Soc. 2018;XX(XX):1–3. (Ahead of print).
   Google Scholar
• Enstrom J, Froding I, Giske CG, et al. USA300 methicillin resistant Staphylococcus aureus in Stockholm, Sweden, from 2008 to 2016. PLoS One. 2018;13(11):e0205761. doi:10.1371/journal.pone.020576130403684
   PubMed Web of Science ®Google Scholar
• George M, Iramiot JS, Muhindo R, Olupot-Olupot P, Nanteza A. Bacterial aetiology and antibiotic susceptibility profile of post-operative sepsis among surgical patients in a tertiary hospital in rural Eastern Uganda. Microbiol Res J Int. 2018;24(2):1–8. doi:10.9734/MRJI
   Google Scholar
• Sutter DE, Milburn E, Chukwuma U, Dzialowy N, Maranich AM, Hospenthal DR. Changing susceptibility of Staphylococcus aureus in a US pediatric population. Pediatrics. 2016;137:e20153099. doi:10.1542/peds.2015-309926933211
   PubMed Web of Science ®Google Scholar
• Acree ME, Morgan E, David MZ. Staphylococcus aureus infections in Chicago, 2006–2014: increase in CA-MSSA and decrease in MRSA incidence. Infect Control Hosp Epidemiol. 2017;38:1226–1234. doi:10.1017/ice.2017.17728903801
   PubMed Web of Science ®Google Scholar
• O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. Rev Antimicrob Resist. 2016;84.
   Google Scholar
• David MZ, Daum RS. Treatment of Staphylococcus aureus infections. Curr Top Microbiol Immunol. 2017;409:325–383. doi:10.1007/82_2017_4228900682
   PubMed Web of Science ®Google Scholar
• Leong HN, Kurup A, Tan MY, et al. Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics. Infect Drug Resist. 2018;11:1959–1974. doi:10.2147/IDR.S17236630464538
   PubMed Web of Science ®Google Scholar
• Tang J, Hu J, Kang L, Deng Z, Wu J, Pan J. The use of vancomycin in the treatment of adult patients with methicillin-resistant Staphylococcus aureus (MRSA) infection: a survey in a tertiary hospital in China. Int J Clin Exp Med. 2015;8(10):19436–19441.26770588
   PubMed Web of Science ®Google Scholar
• Goswami NN, Trivedi HR, Goswami APP, Patel TK, Tripathi CB. Antibiotic sensitivity profile of bacterial pathogens in postoperative wound infections at a tertiary care hospital in Gujarat, India. J Pharmacol Pharmacother. 2011;2:158–164. doi:10.4103/0976-500X.8327921897707
   PubMedGoogle Scholar
• Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42(15):1411–1423. doi:10.2165/00003088-200342150-0000714674791
   PubMed Web of Science ®Google Scholar
• Natsumoto B, Yokota K, Omata F, Furukawa K. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection. 2014;42(6):1007–1012. doi:10.1007/s15010-014-0674-525119433
   PubMed Web of Science ®Google Scholar
• Lee CH, Wang MC, Huang IW, Chen FJ, Lauderdale TL. Development of daptomycin non susceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin resistant Staphylococcus aureus during high-dose daptomycin treatment. Antimicrob Agents Chemother. 2010;54:4038–4040. doi:10.1128/AAC.00533-1020585116
   PubMed Web of Science ®Google Scholar
• Sabat AJ, Tinelli M, Grundmann H, et al. Daptomycin resistant Staphylococcus aureus clinical strain with novel non-synonymous mutations in the mprF and vraS genes: A new insight into daptomycin resistance. Front Microbiol. 2018;9:2705. doi:10.3389/fmicb.2018.0270530459746
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Available from: https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf. Accessed February 27, 2017.
   Google Scholar
• Andersson DI, Hughes D, Kubicek-Sutherland JZ. Mechanisms and consequences of bacterial resistance to antimicrobial peptides. Drug Resist Updates. 2016;26:43–57. doi:10.1016/j.drup.2016.04.002
   PubMed Web of Science ®Google Scholar
• Guilhelmelli F, Vilela N, Albuquerque P, Derengowski LdS, Silva-Pereira I, Kyaw CM. Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance. Front Microbiol. 2013;4:353. doi:10.3389/fmicb.2013.0007724367355
   PubMed Web of Science ®Google Scholar
• Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005;3(3):238–250. doi:10.1038/nrmicro109815703760
   PubMed Web of Science ®Google Scholar
• Taheri B, Mohammadi M, Nabipour I, Momenzadeh N, Roozbehani M, Bhunia A. Identification of novel antimicrobial peptide from Asian sea bass (lates calcarifer) by in silico and activity characterization. PLoS One. 2018;13(10):e0206578. doi:10.1371/journal.pone.020657830365554
   PubMed Web of Science ®Google Scholar
• Sanches PRS, Carneiro BM, Batista MN, et al. A conjugate of the lytic peptide hecate and gallic acid: structure, activity against cervical cancer, and toxicity. Amino Acids. 2015;47(7):1433–1443. doi:10.1007/s00726-015-1980-725868656
   PubMed Web of Science ®Google Scholar
• Jelinkova P, Splichal Z, Jimenez AMJ, et al. Novel vancomycin-peptide conjugate as potent antibacterial agent against vancomycin-resistant. Infect Drug Resist 2018;11:1807–1817. doi:10.2147/IDR.S16097530349337
   PubMed Web of Science ®Google Scholar
• Leszczyńska K, Namiot A, Janmey PA, Bucki R. Modulation of exogenous antibiotic activity by host cathelicidin LL-37. APMIS. 2010;118:830–836. doi:10.1111/j.1600-0463.2010.02667.x20955455
   PubMed Web of Science ®Google Scholar
• Koppen BC, Mulder PPG, de Boer L, et al. Synergistic microbicidal effect of cationic antimicrobial peptides and teicoplanin against planktonic and biofilm-encased Staphylococcus aureus. Int J Antimicrob Agents. 2019;53(2):143–151. doi:10.1016/j.ijantimicag.2018.10.00230315918
   PubMed Web of Science ®Google Scholar
• Hostettman K, Hostettman M. Methods in plant biochemistry, in plant phenolics, ed. P. M. Dey and J. B. Harbone. 1989;1:493.
   Google Scholar
• Roberts JC. Naturally occurring xanthones. Chem Rev. 1961;61(6):591–605. doi:10.1021/cr60214a003
   Web of Science ®Google Scholar
• Gales L, Damas AM. Xanthones-a structural perspective. Curr Med Chem. 2005;12(21):2499–2515.16250874
   PubMed Web of Science ®Google Scholar
• Pinto MM, Sousa ME, Nascimento MS. Xanthone derivatives: new insights in biological activities. Curr Med Chem. 2005;12(21):2517–2538.16250875
   PubMed Web of Science ®Google Scholar
• Na Y. Recent cancer drug development with xanthone structures. J Pharm Pharmacol. 2009;61(6):707–712. doi:10.1211/jpp/61.06.000219505360
   PubMed Web of Science ®Google Scholar
• Panda SS, Chand M, Sakuja R, Jain SC. Xanthones as potential antioxidants. Curr Med Chem. 2013;20(36):4481–4507.23834190
   PubMed Web of Science ®Google Scholar
• Chen X, Leng J, Rakesh KP, et al. Synthesis and molecular docking studies of xanthone attached amino acids as potential antimicrobial and anti-inflammatory agents. Med Chem Commun. 2017;8:1706–1719. doi:10.1039/C7MD00209B
   Web of Science ®Google Scholar
• Miklasinska-Majdanik M, Kepa M, Wojtyczka RD, et al. Phenolic compounds diminish antibiotic resistance of Staphylococcus aureus clinical strains. Int J Environ Res Public Health. 2018;15:E2321. doi:10.3390/ijerph1506118830360435
   PubMed Web of Science ®Google Scholar
• Shi SF, Jia JF, Guo XK, et al. Reduced Staphylococcus aureus biofilm formation in the presence of chitosan-coated iron oxide nanoparticles. Int J Nanomed. 2017;11:6499–6506. doi:10.2147/IJN.S41371
   Web of Science ®Google Scholar
• Morones JR, Elechiguerra JL, Camacho A, Ramirez JT. The bactericidal effect of silver nanoparticles. Nanotechnol. 2005;16:2346–2353. doi:10.1088/0957-4484/16/10/059
   PubMed Web of Science ®Google Scholar
• Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv. 2008;27:76–83. doi:10.1016/j.biotechadv.2008.09.00218854209
   PubMed Web of Science ®Google Scholar
• Duran N, Marcato P, De Conti R, Alves O. Potential use of silver nanoparticles on pathogenic bacteria, their toxicity and possible mechanisms of action. J Braz Chem Soc. 2010;21:949. doi:10.1590/S0103-50532010000600002
   Web of Science ®Google Scholar
• Ruden S, Hilpert K, Berditsch M, Wadhwani P, Ulrich A. Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides. Antimicrob Agents Chemother. 2009;53:3538. doi:10.1128/AAC.01106-0819528287
   PubMed Web of Science ®Google Scholar
• Kora AJ, Rastogi L. Enhancement of antibacterial activity of capped silver nanoparticles in combination with antibiotics, on model gram-negative and gram-positive bacteria. Bioinorg Chem Appl. 2013;2013:871097. doi:10.1155/2013/87109723970844
   PubMed Web of Science ®Google Scholar
• Thirumurugan G, Rao S, Dhanaraju M. Elucidating pharmacodynamics interaction of silver nanoparticle-topical deliverable antibiotics. Sci Rep. 2016;6:29982. doi:10.1038/srep2998227427207
   PubMed Web of Science ®Google Scholar
• Rahim K, Mohamed A. Bactericidal and antibiotic 241 synergistic effect of nanosilver against methicillin-resistant Staphylococcus aureus. Jundishapur J Microbiol. 2015;8:11.
   Web of Science ®Google Scholar
• Das P, Saulnier E, Carlucci C, Allen-Vercoe E, Shah V, Walker VK. Interaction between a broad-spectrum antibiotic and silver nanoparticles in a human gut ecosystem. J Nanomed Nanotechnol. 2016;7(5):1000408.
   Google Scholar
• Surwade P, Ghildyal C, Weikel C, et al. Augmented antibacterial activity of ampicillin with silver nanoparticles against methicillin-resistant Staphylococcus aureus (MRSA). J Antibiotics. 2019;72(1):50–53. doi:10.1038/s41429-018-0111-630361634
   PubMed Web of Science ®Google Scholar
• Manukumar HM, Chandrasekhar B, Rakesh KP, et al. Novel T-C@AgNPs mediated biocidal mechanism against biofilm associated methicillin-resistant Staphylococcus aureus (Bap-MRSA) 090, cytotoxicity and its molecular docking studies. Med Chem Commun. 2017;8:2181–2194. doi:10.1039/C7MD00486A
   Web of Science ®Google Scholar
• Xu Z, Manukumar HM, Rakesh KP, et al. Role of BP*C@AgNPs in Bap-dependent multicellular behavior of clinically important methicillin-resistant Staphylococcus aureus (MRSA) biofilm adherence: a key virulence study. Microb Pathog. 2018;123:275–284. doi:10.1016/j.micpath.2018.07.02530041001
   PubMed Web of Science ®Google Scholar
• O’Brien EC, McLoughlin RM. Considering the ‘alternatives’ for next-generation anti-Staphylococcus aureus Vaccine Development. Trends in Mol Med. 2019;25(3):S1471–4914.
   Web of Science ®Google Scholar
• Willis LM, Whitfield C. Structure, biosynthesis, and function of bacterial capsular polysaccharides synthesized by ABC transporter-dependent pathways. Carbohydr Res. 2013;378:35–44. doi:10.1016/j.carres.2013.05.00723746650
   PubMed Web of Science ®Google Scholar
• Trotter CL, McVernon J, Ramsay ME, et al. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine. 2008;26:4434–4445. doi:10.1016/j.vaccine.2008.05.07318617296
   PubMed Web of Science ®Google Scholar
• O’Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev. 2004;17:218–234.14726462
   PubMed Web of Science ®Google Scholar
• Cocchiaro JL, Gomez MI, Risley A, Solinga R, Sordelli DO, Lee JC. Molecular characterization of the capsule locus from non-typeable Staphylococcus aureus. Mol Microbiol. 2006;59:948–960. doi:10.1111/j.1365-2958.2005.04978.x16420363
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Karakawa WW, Vann WF, Robbins JB. Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis. 1984;2:85–91.6232086
   PubMed Web of Science ®Google Scholar
• Hochkeppel HK, Braun DG, Vischer W, et al. Serotyping and electron microscopy studies of Staphylococcus aureus clinical isolates with monoclonal antibodies to capsular polysaccharide types 5 and 8. J Clin Microbiol. 1987;25:526–530.2437148
   PubMed Web of Science ®Google Scholar
• Nanra JS, Timofeyeva Y, Buitrago SM, et al. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design. Vaccine. 2009;27:3276–3280. doi:10.1016/j.vaccine.2009.01.06219200819
   PubMed Web of Science ®Google Scholar
• Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002;346:491–496. doi:10.1056/NEJMoa01129711844850
   PubMed Web of Science ®Google Scholar
• Fattom A, Matalon A, Buerkert J, et al. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: phase III randomized study. HumVaccin ImmunoTher. 2015;11:632–641.
   Google Scholar
• Rozemeijer W, Fink P, Rojas E, et al. Evaluation of approaches to monitor Staphylococcus aureus virulence factor expression during human disease. PLoS One. 2015;10(2):e0116945. doi:10.1371/journal.pone.011694525719409
   PubMed Web of Science ®Google Scholar
• Begier E, Seiden DJ, Patton M, et al. SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies. Vaccine. 2017;35(8):1132–1139. doi:10.1016/j.vaccine.2017.01.02428143674
   PubMed Web of Science ®Google Scholar
• Frenck RJ, Creech CB, Sheldon EA, et al. Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): results from a first-in-human randomised, placebo-controlled phase 1/2 study. Vaccine. 2017;35(2):375–384. doi:10.1016/j.vaccine.2016.11.01027916408
   PubMed Web of Science ®Google Scholar
• Creech CB, Frenck RJ, Sheldon EA, et al. Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: results of a randomised trial. Vaccine. 2017;35(2):385–394. doi:10.1016/j.vaccine.2016.11.03227866765
   PubMed Web of Science ®Google Scholar
• Marshall H, Nissen M, Richmond P, et al. Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study. J Infect. 2016;73(5):437–454. doi:10.1016/j.jinf.2016.08.00427519620
   PubMed Web of Science ®Google Scholar
• Nissen M, Marshall H, Richmond P, et al. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. Vaccine. 2015;33(15):1846–1854. doi:10.1016/j.vaccine.2015.02.02425707693
   PubMed Web of Science ®Google Scholar
• Fowler VG, Allen KB, Moreira ED, et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. J Am Med Assoc. 2013;309(13):1368–1378. doi:10.1001/jama.2013.3010
   PubMed Web of Science ®Google Scholar
• Xu X, Zhu H, Lv H. Safety of Staphylococcus aureus four-antigen and three-antigen vaccines in healthy adults: a meta-analysis of randomized controlled trials. Hum Vaccin Immunother. 2018;14(2):314–321. doi:10.1080/21645515.2017.139554029064736
   PubMed Web of Science ®Google Scholar
• Dupont CD, Scully IL, Zimnisky RM, et al. Two vaccines for Staphylococcus aureus induce a B-cell mediated immune response. mSphere. 2018;3:e00217–e18. doi:10.1128/mSphere.00217-1830135219
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr, Creech CB, Sheldon EA, et al. Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): results from a first-in-human randomised, placebo-controlled phase 1/2 study. Vaccine. 2017;35:375–384. doi:10.1016/j.vaccine.2016.11.01027916408
   PubMed Web of Science ®Google Scholar
• Jansen KU, Knirsch C, Anderson AS. The role of vaccines in preventing bacterial antimicrobial resistance. Nat Med. 2018;24:10–20. doi:10.1038/nm.446529315295
   PubMed Web of Science ®Google Scholar
• Mohamed N, Wang MY, Le Huec JC, et al. Vaccine development to prevent Staphylococcus aureus surgical-site infections. Br J Surgery. 2017;104:e41–e54. doi:10.1002/bjs.10454
   PubMed Web of Science ®Google Scholar
• Berube BJ, Bubeck Wardenburg J. Staphylococcus aureus alpha-toxin: nearly a century of intrigue. Toxins. 2013;5:1140–1166.23888516
   PubMed Web of Science ®Google Scholar
• Genestier AL, Michallet MC, Prevost G, et al. Staphylococcus aureus Panton-Valentine LEUKOCIDIN directly targets mitochondria and induces bax-independent apoptosis of human neutrophils. J Clin Invest. 2005;115:3117–3127. doi:10.1172/JCI2268416276417
   PubMed Web of Science ®Google Scholar
• Adhikari RP, Ajao AO, Aman MJ, et al. Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J Infect Dis. 2012;206:915–923. doi:10.1093/infdis/jis46222807524
   PubMed Web of Science ®Google Scholar
• Landrum ML, Lalani T, Niknian M, et al. Safety and immunogenicity of a recombinant Staphylococcus aureus alpha-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adults. Hum Vaccin Immunother. 2017;13(4):791–801. doi:10.1080/21645515.2016.124832628010246
   PubMed Web of Science ®Google Scholar
• Korea CG, Balsamo G, Pezzicoli A, et al. Staphylococcal Esx proteins modulate apoptosis and release of intracellular Staphylococcus aureus during infection in epithelial cells. Infect Immun. 2014;82(10):4144–4153. doi:10.1128/IAI.01576-1425047846
   PubMed Web of Science ®Google Scholar
• Burts ML, Williams WA, DeBord K, Missiakas DM. EsxA and EsxB are secreted by an ESAT-6-like system that is required for the pathogenesis of Staphylococcus aureus infections. Proc Natl Acad Sci U S A. 2005;102(4):1169–1174. doi:10.1073/pnas.040562010215657139
   PubMed Web of Science ®Google Scholar
• Xu C, Zhang B-Z, Lin Q, et al. Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection. BMC Infect Dis. 2018;18:195. doi:10.1186/s12879-018-3104-y29699491
   PubMed Web of Science ®Google Scholar
• Parker D, Prince A. Immunopathogenesis of Staphylococcus aureus pulmonary infection. Semin Immunopathol. 2012;34:281–297. doi:10.1007/s00281-011-0291-722037948
   PubMed Web of Science ®Google Scholar
• Becker S, Frankel MB, Schneewind O, Missiakas D. Release of protein A from the cell wall of Staphylococcus aureus Proc Natl Acad Sci USA. 2014;111:1574–1579. doi:10.1073/pnas.131718111124434550
   PubMed Web of Science ®Google Scholar
• Pauli NT, Kim HK, Falugi F, et al. Staphylococcus aureus infection induces protein A-mediated immune evasion in humans. J Exp Med. 2014;211:2331–2339. doi:10.1084/jem.2014140425348152
   PubMed Web of Science ®Google Scholar
• Kim HK, Cheng AG, Kim HY, Missiakas DM, Schneewind O. Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections. J Exp Med. 2010;207:1863–1870. doi:10.1084/jem.2009251420713595
   PubMed Web of Science ®Google Scholar
• Yang Y, Yu R, Yang X, et al. Protection against Staphylococcus aureus and tetanus infections by a combined vaccine containing SasA and TeNT-Hc in mice. Mol Med Rep. 2017;15:2369–2373. doi:10.3892/mmr.2017.622728259925
   PubMed Web of Science ®Google Scholar
• Cava F, Lam H, de Pedro MA, Waldor MK. Emerging knowledge of regulatory roles of D-amino acids in bacteria. Cell Mol Life Sci. 2011;68:817–831. doi:10.1007/s00018-010-0571-821161322
   PubMed Web of Science ®Google Scholar
• Moscoso M, Garcıa P, Cabral MP, Rumbo C, Bou G. A D-Alanine auxotrophic live vaccine is effective against lethal infection caused by Staphylococcus aureus. Virulence. 2018;9(1):604–620. doi:10.1080/21505594.2017.141772329297750
   PubMed Web of Science ®Google Scholar
• Zhang B-Z, Cai J, Yu B, et al. Immunotherapy targeting adenosine synthase a decreases severity of Staphylococcus aureus infection in mouse model. J Infect Dis. 2017;216:245–253. doi:10.1093/infdis/jix29028633319
   PubMed Web of Science ®Google Scholar
• Mcadow M, Dedent AC, Emolo C, et al. Coagulases as determinants of protective immune responses against Staphylococcus aureus. Infect Immun. 2012;80:3389e98. doi:10.1128/IAI.06224-1122825443
   PubMed Web of Science ®Google Scholar
• Pozzi C, Bagnoli F, Rappuoli R. Staphylococcus aureus coagulase R domain, a new evasion mechanism and vaccine target. J Exp Med. 2016;213:292. doi:10.1084/jem.2015191626951364
   PubMed Web of Science ®Google Scholar
• Guggenberger C, Wolz C, Morrissey JA, Heesemann J. Two distinct coagulase dependent barriers protect Staphylococcus aureus from neutrophils in a three dimensional in vitro infection model. PLoS Pathog. 2012;8:e1002434. doi:10.1371/journal.ppat.100243422253592
   PubMed Web of Science ®Google Scholar
• Qian M, Zhao T, Li R, et al. Targeting the R domain of coagulase by active vaccination protects mice against lethal Staphylococcus aureus infection. Microbes Infect. 2018:S1286–4579. (18)30177-1.
   Web of Science ®Google Scholar
• Krakauer T, Pradhan K, Stiles BG. Staphylococcal superantigens spark host-mediated danger signals. Front Immunol. 2016;7:23. doi:10.3389/fimmu.2016.0002326870039
   PubMed Web of Science ®Google Scholar
• Kulhankova K, King J, Salgado-Pabon W. Staphylococcal toxic shock syndrome: superantigen-mediated enhancement of endotoxin shock and adaptive immune suppression. Immunol Res. 2014;59:182–187. doi:10.1007/s12026-014-8538-824816557
   PubMed Web of Science ®Google Scholar
• Mantis NJ. Vaccines against the category B toxins: staphylococcal enterotoxin B, epsilon toxin and ricin. Adv Drug Deliv Rev. 2005;57:1424e1439. doi:10.1016/j.addr.2005.01.01715935880
   PubMed Web of Science ®Google Scholar
• Choi JY, Shin S, Kim NY, et al. A novel staphylococcal enterotoxin B subunit vaccine candidate elicits protective immune response in a mouse model. Toxicon. 2017;131:68–77. doi:10.1016/j.toxicon.2017.03.01228359755
   PubMed Web of Science ®Google Scholar
• Tkaczyk C, Hua L, Varkey R, et al. Identification of anti-alpha toxin mAbs that reduce severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin Vaccine Immunol. 2012;19:377–385. doi:10.1128/CVI.05589-1122237895
   PubMed Web of Science ®Google Scholar
• Kennedy AD, Bubeck Wardenburg J, Gardner DJ, et al. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis. 2010;202:1050–1058. doi:10.1086/65604320726702
   PubMed Web of Science ®Google Scholar
• Ragle BE, Bubeck Wardenburg J. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun. 2009;77:2712–2718. doi:10.1128/IAI.00115-0919380475
   PubMed Web of Science ®Google Scholar
• Cheung GY, Otto M. The potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections. Expert Opin Ther Targets. 2012;16(6):601–612. doi:10.1517/14728222.2012.68257322530584
   PubMed Web of Science ®Google Scholar
• Varshney AK, Kuzmicheva GA, Lin J, et al. A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia. PLoS One. 2018;13(1):e0190537. doi:10.1371/journal.pone.019053729364906
   PubMed Web of Science ®Google Scholar
• Kalali Y, Haghighat S, Mahdavi M. Passive immunotherapy with specific IgG fraction against autolysin: analogous protectivity in the MRSA infection with antibiotic therapy. Immunol Lett. 2018;S0165–2478. (18)30132-9.
   Web of Science ®Google Scholar
• Diep BA, Le VTM, Visram ZC, et al. Improved protection in a rabbit model of community-associated methicillin-resistant Staphylococcus aureus necrotizing pneumonia upon neutralization of leukocidins in addition to alpha-hemolysin. Antimicrob Agents Chemother. 2016;60(10):6333–6340. doi:10.1128/AAC.01213-1627527081
   PubMed Web of Science ®Google Scholar
• Stulik L, Rouha H, Labrousse D, et al. Preventing lung pathology and mortality in rabbit Staphylococcus aureus pneumonia models with cytotoxin-neutralizing monoclonal IgGs penetrating the epithelial lining fluid. Sci Rep. 2019;9:5339. doi:10.1038/s41598-019-41826-630926865
   PubMed Web of Science ®Google Scholar
• Haghighat S, Siadat SD, Rezayat Sorkhabadi SM, et al. Recombinant PBP2a as a vaccine candidate against methicillin-resistant Staphylococcus aureus: immunogenicity and protectivity. Microb Pathog. 2017;108:32–39. doi:10.1016/j.micpath.2017.04.03728457901
   PubMed Web of Science ®Google Scholar
• Naghshbandi RZ, Haghighat S, Mahdavi M. Passive immunization against methicillin resistant Staphylococcus aureus recombinant PBP2a in sepsis model of mice: comparable results with antibiotic therapy. Int Immunopharmacol. 2018;56:186–192. doi:10.1016/j.intimp.2018.01.03529414649
   PubMed Web of Science ®Google Scholar
• Gerlach D, Guo Y, De Castro C, et al. Methicillin-resistant Staphylococcus aureus alters cell wall glycosylation to evade immunity. Nature. 2018;563(7733):705–709. doi:10.1038/s41586-018-0730-x30464342
   PubMed Web of Science ®Google Scholar